Trial Profile
An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus Infections in High-risk Pediatric Allogeneic Hematopoietic Cell Transplant Recipients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Brincidofovir (Primary) ; Antivirals; Cidofovir; Ganciclovir; Ribavirin; Valganciclovir
- Indications Adenovirus infections
- Focus Pharmacokinetics; Registrational
- Acronyms AdAPT; Study 999
- Sponsors Chimerix
- 29 Oct 2020 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.
- 16 Jul 2020 This trial has been completed in United Kingdom, according to European Clinical Trials Database record. (2019-05-30)
- 07 Feb 2020 This trial has been completed in Poland,according to European Clinical Trials Database record.